Pharmaceutical Companies Focus on Rare Diseases: Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business

**Pharmaceutical Companies Announce New Agreements and Acquisitions**

Recent activity in the pharmaceutical sector reveals a focus on rare diseases and oncology, with Eli Lilly, Servier, and Avenzo making significant moves. These deals encompass a range of therapeutic areas, including gastrointestinal disorders, muscular dystrophy, and innovative cancer treatments.

Servier will acquire Edgewise Therapeutics’ muscular dystrophy business, marking an expansion into this rare disease area. Hanmi Pharmaceutical entered a licensing agreement with Eli Lilly, potentially collaborating on gastrointestinal disorder treatments. Avenzo and Rallybio have entered into a merger agreement, which could lead to the development of next-generation cancer therapeutics. These transactions demonstrate the pharmaceutical industry’s continued interest in addressing unmet medical needs through strategic investments and partnerships.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI